Antibody-Drug Conjugates for Cancer Therapy.

2016-07-11

Parslow, Adam C

Parakh, Sagun

Lee, Fook-Thean

Gan, Hui K

Scott, Andrew M

ADC

antibody–drug conjugate

cancer

immunotherapy

monoclonal antibodies

resistance

Journal Article

0000-0003-3891-2489

0000-0002-6656-295X

10.3390/biomedicines4030014

Antibody-drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance.

link

Biomedicines 2016; 4(3): E14

Biomedicines

2227-9059